Verrica Q2 revenue falls to $5.9 million; net loss widens to $13.2 million
Verrica Pharmaceuticals reported second-quarter 2026 results on August 6, 2026. Total revenue fell to $5.9 million from $12.7 million a year earlier, and the company posted a net loss of $13.2 million compared with net income of $0.2 million, even though U.S. YCANTH product revenue rose. The company also announced a credit facility of up to $27.5 million with an entity controlled by its chairman and largest shareholder, which it says could extend its cash runway into 2028.
Key points
- Total revenue was $5.9 million versus $12.7 million in Q2 2025, which included $8.0 million of one-time Torii milestone revenue in the prior year.
- U.S. YCANTH net product revenue was $5.1 million, up from $4.5 million, with dispensed applicator units up about 46% year over year to 19,626.
- Q2 2026 net loss was $13.2 million, or $0.62 per share, versus net income of $0.2 million, or $0.02 per share, in Q2 2025.
- Cash was $11.2 million at June 30, 2026, down from $30.1 million at December 31, 2025; the credit facility is up to $27.5 million with an entity controlled by Paul B. Manning.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.